Literature DB >> 22323622

Imaging diagnosis, transurethral endoscopic observation, and management of 43 cases of persistent and refractory hematospermia.

Yan-Feng Li1, Pei-He Liang, Zhong-Yi Sun, Yong Zhang, Gang Bi, Bo Zhou, Ke Li, Wei Bai, Luo-Fu Wang, Jun Zhang, Feng-Shuo Jin.   

Abstract

The goal of this study was to explore minimally invasive transurethral imaging and surgery for the treatment of severe, persistent hematospermia in cases that were refractory to conservative treatments. The study included 43 patients (aged 22-77 years; average, 44.6 years) with long-lasting, severe hematospermia, accompanied by discomfort or pain in the lumbosacral or perineal region, dysuria, frequent micturition, decreased semen volume, and/or azoospermia. Patient symptoms had persisted for 1 to 10 years (average, 5.3 years). Computed tomography or magnetic resonance imaging of each patient was evaluated, and transurethral surgery was performed. The causes of hematospermia were identified in all 43 patients, and their ejaculatory duct obstruction or seminal vesiculitis was successfully treated. No serious intraoperative or postoperative complications occurred. Pathologic analyses revealed that all of the resected or biopsied seminal vesicle tissues had chronic nonspecific inflammation in the seminal vesicle wall, and no tumors were identified. Preoperative symptomology of hematospermia disappeared in all patients followed up for 2 to 30 months (average, 16 months). A single patient experienced recurrence at 11 months and had a second minimally invasive surgery that was curative. A total of 95.3% (41 of 43) of the patients experienced normal orgasmic intensity after surgery. Magnetic resonance imaging is a valuable and accurate diagnostic method for the identification of causative factors underlying hematospermia. Transurethral dilation of ejaculatory ducts, incision of the verumontanum or the distal end of the ejaculatory ducts, and incision or resection of the relevant cysts represent simple, safe, and reliable approaches for the management of refractory cases of hematospermia that do not respond to conservative treatments.

Entities:  

Mesh:

Year:  2012        PMID: 22323622     DOI: 10.2164/jandrol.111.015487

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  6 in total

1.  Transurethral endoscopic treatment of seminal vesicle cysts (report of seven cases).

Authors:  Ming-Song Wang; Bo-Jun Li; Zao-Ming Huang; Yong Luo; Yong Zhang; Ke Li; Ke-Qin Zhang; Feng-Shuo Jin; Yan-Feng Li
Journal:  Int Urol Nephrol       Date:  2015-03-21       Impact factor: 2.370

2.  The performance of transrectal ultrasound in the diagnosis of seminal vesicle defects: a comparison with magnetic resonance imaging.

Authors:  Xu Chen; Hua Wang; Rong-Pei Wu; Hui Liang; Xiao-Peng Mao; Cheng-Qiang Mao; Hong-Zhang Zhu; Shao-Peng Qiu; Dao-Hu Wang
Journal:  Asian J Androl       Date:  2014 Nov-Dec       Impact factor: 3.285

Review 3.  Detecting diseases of neglected seminal vesicles using imaging modalities: A review of current literature.

Authors:  Gautam Dagur; Kelly Warren; Yiji Suh; Navjot Singh; Sardar A Khan
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-05

4.  Etiology of 305 cases of refractory hematospermia and therapeutic options by emerging endoscopic technology.

Authors:  Liang-Gong Liao; Yan-Feng Li; Yong Zhang; Ke Li; Tong Zhu; Bo-Jun Li; Qi Wang; Xu-Dong Liu; Yong Luo; Bo Zhou; Jun Jiang
Journal:  Sci Rep       Date:  2019-03-22       Impact factor: 4.379

Review 5.  Retrograde ejaculation, painful ejaculation and hematospermia.

Authors:  Arie Parnham; Ege Can Serefoglu
Journal:  Transl Androl Urol       Date:  2016-08

6.  Transurethral resection of ejaculatory duct combined with seminal vesiculoscopy for management of persistent or recurrent hemospermia in men with ejaculatory duct obstruction.

Authors:  Zheng-Ju Ren; Bo Yang; Dong-Liang Lu; Sheng-Zhuo Liu; Lu-Chen Yang; Lin Cun Wang; Zhu-Feng Peng; Liang-Ren Liu; Qiang Dong
Journal:  BMC Urol       Date:  2020-03-23       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.